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ECONOMIC ASPECTS OF CRITICAL LIMB
ISCHAEMIA
The diagnostic and therapeutic management of
patients with critical limb ischaemia has been studied
extensively in a number of settings. Unfortunately,
results are not necessarily reported in a way that ren-
ders comparisons possible.
D 5.1.1
Costs of Diagnostic Procedures
The total costs of diagnostic tests for patients with crit-
ical limb ischaemia were estimated for the United
Kingdom in 1995 by Hart and Guest! in a review of the
available statistics and a panel survey. They found a
total figure of $15.2 million (Euro 14.1 million) at 1994
prices, for tests for approximately 200,000 patients suf-
fering from CLI. Using this figure as a denominator,
the average cost of diagnostic procedures per pati ent
would be $76 (Euro 71) per patient per year. This fig-
ure, however, does not reflect the wide variations of
costs between the patients who will be monitored with
simple blood tests and Doppler ultrasound and those
who will undergo an arteriogram. Also, the computa-
tion of a yearly average cost may be appropriate for
budgeting purposes but less useful for medical deci-
sion making than the cost per patient or case type, for
which the literature contains modelled estimates but
no actual data. The total cost of tests represents less
than 10% of the total cost of the management of CLI,
which may explain why little research has been done
in that field .
D 5.1.2
Costs of Treatment for Critical Limb Ischaemia
Studies published on the cost of treating CLI present
data on surgical revascularisation and PTA (both suc-
cessful and failed) as used in Table 56 and Figure 26
and also on primary amputation. Figures are often
presented together in the articles, but an attempt has
been made in this discussion to separate patients for
whom the initial decision was revascularisation from
those who underwent primary amputation. The
rationale is that the two patients groups (primary
revascularisation vs primary amputation) are likely to
be different in terms of anatomy, severity of lesions,
and general health.
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Proximal grafts andsients
The costs of treating patients with proximal disease
appear to be lower than those for patients with distal
occlusion. Drummond and Davies- report an estimat-
ed $11,000(Euro 10,230) cost for proximal grafts. Their
figure is close to the $10,000 (Euro 9,300) reported for
iliac grafts by Kinnison et al,3 who also reported lower
costs of $3,075 (Euro 2,860) and a shorter length of stay
for treating proximal disease with endovascular pro-
cedures. A nonrandomised comparison of aortoiliac
stenting versus surgery indicated that the cost per
limb treated did not differ significantly ($9,161 [Euro
8,520] vs $10,585 [Euro 9,844], respectively}'.
However, the significant differences in patient popula-
tions and the absence of documented follow-up costs
and cost per patient limits the usefulness of this result.
Distallesion bypass and PTA
A number of studies have estimated the costs of treat-
ing distal arterial stenoses with bypass or PTA using a
variety of methods-prospective, retrospective, opin-
ion-based, or decision models-which may render
comparisons between the reported results hazardous.
In one study, the 1997 costs of surgical treatment,
without comparison of strategies, were estimated
prospectively from a consecutive series of 101 patients
and 109 fernorodistal bypass grafts. The one comorbid
condition identified was diabetes, and the follow-up
was 12 months. Hospital costs were from the UK
National Health Service schedule; non-health care
costs were not included. Median costs for revasculari-
sation were $7,200 (Euro 6,696) and $28,433 (Euro
26,443) for secondary amputation, including rehabili-
tation and prosthesis.s
Singh et al (1996)6similarly documented costs in the
United States, including medical and non-health care
costs with a 12-month follow-up for patients with CLI
but without data on comorbid conditions. The cost of
successful revascularisation was $11,277 (Euro 10,488)
versus $21,545 (Euro 20,037) for failed procedures.
These results confirmed the twofold cost increase
when revascularisation fails and results in an amputa-
tion or patient death. For example, Raviola et al? had
previously reported 1985 health care costs of $20,300
(Euro 18,879) for uncomplicated bypass surgery and
$28,700 (Euro 26,691) for complications required
bypass revision with costs rising to $42,000 (Euro
39,060) when secondary amputation was required. In
1986, Mackey et alS found a higher total cost of $30,600
(Euro 28,458) attributable to a longer follow-up,
including rehospitalisations and follow-up for sue-
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Table 56: Costs of treatment of CLl
Cost Cost s Mean reported Time
year Icharges Lesion Ind ication cost (US $) fram e Included
Percutaneous Transluminal Angioplasty:
Hun ink et .11,199513 1990' Costs Fempop Necrosis 27,000 Lifetime In-h osp ital care, PF,
stenosis revis ions.f /u amputations,
I-1unink et al, 199513
d iscounted 5% per annum
1990' Costs Fempop Rest pain 33,000 Lifetim e In-ho spital care, PF,
stenosis revisions, flu amputations,
d iscounted 5% per annum
I-1unink et al, 199513 1990' Costs Fempop Necrosis 36,000 Lifetime In-hosp ital care, PF,
occlusion revis ions, flu amputations,
d iscounted 5% per annum
I-1unink et al, 199513 1990' Costs Fempop Rest pa in 43,000 Lifetime In-hospital care, PF,
occlusion revisions, flu amputations,
d iscounted 5% per annum
I-1unink et al, 199513 1990' Costs Fempop CLI 11,809 Hosp In-ho spital health
admissions care, PF
Kinnison et .11,1985 3 1982' Charges Femoral mixed 2,767 Initial In-ho spital care,
procedure excluding PF
Kinnison et al, 19853 1982' Charges Iliac mixed 3,075 Initial In-hospital care,
procedure exclud ing PF
Bypass:
Yin et al, 1995' 5 1992' Medicare Infrainguinal CLI 17,257 Initial
payments procedure
Yin et al, 1995'5 1992' Medicare Infrainguinal CLI 17,257 Initial
paym ent s procedure
Pana yiotopoulos 1991- NHS Fem-crurall CLI £4,320§ 12 months In-hospital care
et al, 19975 1995t crit eria fern-pedal 6,750:1:
I-1 un ink et .11,199513 1990' costs Fempop necrosis 29,000 Lifetime In-ho spit al care, PF;
vein revisions, flu amputations,
d iscounted 5% per annum
I-1unink et al, 199513 1990' costs Fempop CLI 16,820 Hosp In-hospital
admissions care, PF
I-1unink et al, 199513 1990' costs Fempop rest 35,000 Lifetime In-ho spital care, PF,
vein pain revisions, flu amputations,
discounted 5% per annum
Drummond & 1989t costs Distal CLI 11,000 Long-term In-hospital care, rehab, care
Davies, 19942 18,300:1:
Drummond & 1989t costs Proximal CLI 6,600 "long-term"
Davies, 1994' 11,000:1:
Cheshire ct al, 1992" 1989t costs Fern-crural CLI 15,024 34mo In-hospital care,
25,000:1: outpatient,
Patient costs, revisions
Cheshire et al, 199211 1989t costs Syn thetic CLI 20,416
34mo
Gupta & Veith, 1990'· 1986' charges Fempopl necrosis 22,946 Initial
extra-anatomic procedure
Gupta & Veith, 19901• 1986' charges Fempopl necrosi s 16,928 Initial
extra-anatomic procedure
Raviola et al, 19887 1985' charges Fempop CLI 20,300 N/A
Kinnison et al, 1985' 1982' charges Femoral mix 8,198 Initial
procedure
Kinnison et al, 1985' 1982' charges Iliac mix 10,223 Init ial
procedure
Amputation:
Yin et al, 1995u 1992' Medicare Primary CLI 12,397 Init ial
paym ents procedure
Yin et al, 1995u 1992' Medicare Primary CLI 11,752 Initial
payments procedure
Panayiotopoulos 1991- NHS Primary CLI 12,730§
ct al, 19975 1995t criteria 19,890:1:
Pana yiotopoulos 1991- NHS Secondary CLI 7,066B 12 months In-hospital
ct al, 19975 1995+ criteria 28,440:1: hcalth carc, PF,
Prosth esis, rehab
Drummond & 1989t costs Primary CLI 10,550 "long-term"
Davies, 1994' 17,750:1:
Raviola et .11,19887 1985' charges Secondary CLI 42,200 n/s In-hosp ital hcalthcarc, PF,
Prosthesis, rehab
'USA study, tUK study. :l:Cost adjusted to USS (OECDanalytical dctabasc-e-Ecosante 1998). §~Icdian costs. PF,professional fees.
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Overview of Cost Estimates for Treating CLI
• For details see text and Table 27
• Costs expressed in US dollars and updated to 1997
• Includes professional fees, which were estimated if not included in original study.
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Fig. 26. Overview of cost estimates for treating critical limb ischae mia.
cessful revascularisation. The total cost during a 2-
year follow-up was 556,809 (Euro 52,832) for failed
revascularisation that required reconstruction, sec-
ondary procedures, or amputation..
Costs of revascularisation were reported by a
Danish study (1995) in a retrospective study of 153
patients with a 12-month follow-up included in the
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costs. The average health care costs per patient were
516,667 (Euro 15,500). No data on the severity of dis-
ease or comorbid conditions are ava ilable from this
study apart from the information that 56% patients
had at least one risk factor (diabetes, cerebrovascular,
hypertension, cardiac, pulmonary, renal)", A 1996 cost
of $12,500 (Euro 11,625) for surgical revascularisation,
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including secondary amputation in 20% patients, was
estimated in a Norwegian hospital. Because these data
were not derived from actual patient records but from
expert opinion and literature data, it is only moder-
ately contributive.w The cost figure is similar, how-
ever, to that given by Cheshire et al,'! who reported
from retrospective data a health care cost of $12,500
(Euro 11,625) for the first year of revascularisation
using vein graft and of $17,013 (Euro 15,822) for syn-
thetic grafts.
Hunink compared the hospital cost of patients with
CLI admitted for angioplasty or surgical revasculari-
sation.12,n The costs of angioplasty and surgical revas-
cularisation were, respectively, $11,353 ± $7,658 (Euro
10,558 ± Euro 7,122) and $15,059 ± $7,313(Euro 14,005
± Euro 6,801) when no additional procedure was nec-
essary, whereas additional bypass, angioplasty, or
thrombolysis increased the costs by a mean of $9,003
(Euro 8,373), and debridement or amputation
increased costs by a mean of $24,766 ± $2,241 (Euro
23,032 ± Euro 2,084). These authors point out that the
patient populations were d ifferent with regard to
severity of disease. This also renders doubtful the
comparison made by Jeans et al 14 between the two
procedures. Costing retrospective series of PTA and
surgery, Jeans et al reported a fourfold difference, with
$502 (Euro 467) for PTA and $2,213 (Euro 2,058) for
surgery. Because no patient information and follow-
up data were reported, these figures cannot be consid-
ered reliable. A similar difficulty exists for the inter-
pretation of the study by Kinnison et a13 reporting the
hospital cost for the initial admission of selected
uncomplicated patients treated with femoral PTA or
femoral bypass. The costs were higher than in the
Jeans et al study, but the difference found between the
two procedures was similar ($2,767/Euro 2,573 for
PTA and $8,198/Euro 7,624 for bypass). From an eco-
nomic viewpoint, PTA appears interesting, in that the
cost difference with surgery is not eventually compen-
sated by higher follow-up and complication costs.
Yin et al,ls using a decision-model, documented the
costs for a "typical patient" undergoing surgical revas-
cularisation. Costs and benefits were computed from
the Medicare fee schedule. This included non-health
care costs computed from the estimated lost income
(valued by the average US national daily earnings up
to the age of retirement at 65 years) . The mean cost in
1992 was $17,267 (Euro 16,058) for successful revascu-
larisation, which increased to $17,912 (Euro 16,658)
when the costs of workdays lost were added.t? Gupta
and Veith l 6 documented a mixed figure"of costs and
charges, comparing it with the DRG reimbursement
schedule (see also A 4.1, Perspective in Economics, p
539). The average cost/charge of $16,887 (Euro 15,705)
was reported for uncomplicated successful proce-
dures, and $30,720 (Euro 28,570) for successful but
complicated procedures. A significant difference was
found between the costs/charges depending on
whether the patient had diabetes or a cardiac history.
Results for costs of treatment are summarised in Table
54. A critical issue exposed by this table is the lack of
comparable data, except for successful surgical revas-
cularisation .
Primary amputations
The costs of primary amputations excluding rehabili-
tation were found to vary from $12,000 to $23,000
(Euro 11,160-21,390). The lowest figures were found
by Yin et al in 1992 IS and by Sculpher et alH in 1993/4
(GBE have been converted into US$).They reported
costs of $12,397 to $13,500 (Euro 11,529-12,555); the
non-health care costs of workdays lost represented
less than $1,000. The highest estimate included the
costs of rehabilitation up to $36,000 (Euro 33,480) for
all health care costs including prosthesis. There was a
$2,000 increase in cost when the amputation was
above the knee." Most authors however, report costs
of approximately $20,000 (Euro 18,600). A study in
New Zealand that included non-health care costs fell
into this range, with an estimate of NZ $23,000 per
procedure and confirmed the cost difference between
below- and above-knee amputations."
Raviola et al? reported a $20,000 health care cost for
primary amputation, which was close to the $20,400
figure by Gupta and Veith' ? in 1988. The $23,330 cost
reported by Hart and Guest! for amputation is compa-
rable to the figure of $17,333-$18,167 found in the
United Kingdom by Drummond 2 and Cheshire et
al," using similar methods of cost computations, the
estimated $16,667 from a Norwegian study'? the
$22,000 reported by Hunink et al in a decision model,»
$21,217 found by Panayiotopoulos et aI,Sand $16,927
reported by Singh," All of these studies reported costs
calculated between 1985 and 1994. The higher cost of
$40,563 ± $4,729 reported by Mackey et als in 1985
results from a longer follow-up period.
A 1997 Finnish study documented an important
determinant of the total cost of primary amputation,
which was whether the patient wa s in an institution
(nursing home). This author found that the cost of the
initial procedure and a 5-year follow-up for a patient
in an institution was $13,000 (Euro 12,090), whereas
the cost increased to.$70,000 (Euro 65,100) for a non-
institutionalised patient. This major difference is
explained by the daily cost of surgical wards and reha-
bilitation wards, and by the higher non-health care
Eur J Vase Endovasc Surg Vol 19 Supplement A, June 2000
5236 Economics Aspects of Critical Limb Ischaemia
Table 57: 199-1 Costs of the management of patients with CLI in the United Kingdom
199-1 yearly a\'erage cost per pati ent
Procedure
Family doctor visits and dru gs (ambulatory)
Hospitalisations and minor surgery
Treatment of ulcers
PTA (hospital costs, per admission)
Thrombolysis (hospit al costs, per admission)
Bypass revascularisafion (all grafts)
Adding non-health care costs
Amputation
Adding home care
Costs of caring for an invalid person
cost of providing care to patients who are still living in
their homes.> Some authors have attempted to docu-
ment roughly the non-health care costs of taking care
of an amputee. Although the cost of institutions and
nursing home have been presented previously, these
home costs are separated because they do not result
from actual analysis of databases, but from expert
opinion. The estimated cost of professional nursing
care was $100,000 per year in the United States.s! The
estimated costs of home alterations to accommodate
an amputated patient ranged from $700 for toilet seats
to $25,000 for concrete wheelchair ramps.v
Table 57 presents separately the health care and non-
health care costs in the United Kingdom of managing
patients with CLl, estimated from databases, expert
opinion, and hospital statistics for the year 1994, and
divided by an estimated number of patients concerned
to obtain unit costs.' The difficulty in interpreting and
using these results stems from the heterogeneity of
data sources, and the unclear definition of case-types,
as some of the procedures described such as thrombo-
lysis pertain to a more acute case-type. Thus, they
should be considered as a description of costs, and in
no way as a comparison of therapeutic strategies. This
is, however, the only study that separated clearly the
different components of the total costs .
D 5.1.3
Cost-effectiveness of Diagnostic Strategies
The cost-effectiveness of MRA for planning the treat-
ment of patients with CLl has been evaluated from a
decision-analysis model.P The model tested conven-
tional angiography (reference strategy) and MRA. The
outcomes measured were the length and quality of
life, using the quality-of-well-being scale. The costs
were computed from the viewpoint of society, using
Medicare prospective payment and professional fees.
The estimated cost of MRA and conventional anglo-
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UK£ USS
81 135
1,950 3,250
1,435 2,392
558 930
2,309 3,8-13
5,275 5,455
8,792 9,092
7,282 12,137
11,48-1 19,140
14,345 23,908
graphy were $1,003 (Euro 933) and $1,395 (Euro 1,297),
respectively. Non-health care costs were estimated
from the number of workdays lost, multiplied by the
US national average daily earnings In the baseline
analysis, the gain from using MRA to identify the tar-
get vessels and plan revascularisation procedures was
8.5 healthy years of life per 1,000 patients treated, at a
total cost of $220,000 (Euro 204,600) per 1,000 patients.
Because of uncertainty about the sensitivity and speci-
ficity of the MRA, the authors concluded that, given a
sensitivity equal 92% and a specificity equal to 88%,
the cost-effectiveness was roughly $29,000 (Eur 26,970)
per healthy year of life. This ratio is within the range
of accepted interventions in most countries.D
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D6
CLINICAL TRIAL ISSUES IN CRITICAL LIMB
ISCHAEMIA
D 6.1
Introduction
D 6.1.1
Scope
As with Clinical Trial Issues in "Intermitten t
Claudication (B 6, P 5108), this section is not intended
to be exhaustive but rather focuses on selected contro-
versial issues. Similarly, recommendations made here
are usually not based on solid scientific evidence,
which is rare in this area of trial methodology. In
patients with CLI, trials involving surgical or
endovascular techniques as well as drug therapy are
usually relevant. "Trial" in this context is taken to
mean a study designed to investigate the possible effi-
cacy of one treatment modality compared with anoth-
er. This definition of a trial would exclude a purely
descriptive account of a particular treatment as pre-
sented in most publications on new surgical or
endovascular techniques. Trials in CLI are very rarely
performed in the context of a randomised comparison
between a new technique and an established tech-
nique. Therefore, in assessing the efficacy for a new
interventional technique, one usually has to fall back
on historical comparisons with studies describing pre-
vious techniques. The reliability of such comparisons
depends crucially on the accuracy of description, that
is, reporting standards (see later discussion).
The principal threat to patients with CLI as far as
their legs are concerned is failure to relieve ulceration,
gangrene, or rest pain, leading to the need for a major
amputation. Therefore, only trials primarily designed
to look at the efficacy of a new treatment in the context
of limb salvage will be considered. Patients with
chronic CLI also have a higher risk of cardiovascular "
mortality and morbidity (see Epidemiology, Natural
History, Risk Factors, A 2, P 54). The role of meta-
analysis and decision modelling as an alternative is
considered in Economic Aspects of PAD (A 4, P 539).
After a general discussion of the problems involved in
defining entry criteria and outcome response in all tri-
als in patients with CLI, special issues relating to
interventional trials and drug trials are discussed. For
several decades, patients with CLI could be treated
successfully only by surgery. Most published studies
on the treatment of CLI are descriptive accounts of a
particular technique with no comparative group and,
until recently, not using a standardised method of
reporting. Over the last 10 to 15 years, a number of
publications have described endovascular techniques,
a few comparing them in randomised series with sur-
gical alternatives. Trials of pharmacotherapy are even
more recent and usually follow the conventional
methodology of a randornised controlled trial.
There have been no published trials of pharma-
cotherapy versus an interventional treatment in
patients with CLI. This is partly because no pharma-
cotherapy has yet been perceived to be possibly "as
effective as an alternative interventional technique,
although this has never been tested . Such a compara-
tive trial would pose special problems in terms of
deciding appropriate end points because pharma-
cotherapy that may promote healing in a critically
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